{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T14:03:20Z","timestamp":1793714600587,"version":"4.6.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"National High Level Hospital Clinical Research Funding","award":["2022-PUMCH-B-092"],"award-info":[{"award-number":["2022-PUMCH-B-092"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflamm. Res."],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1007\/s00011-023-01789-x","type":"journal-article","created":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T13:50:11Z","timestamp":1694699411000},"page":"1861-1871","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Association of risk of incident acne and treatment with systemic Janus kinase inhibitors in atopic dermatitis: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"72","author":[{"given":"Chen","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue-Ping","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,14]]},"reference":[{"key":"1789_CR1","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/354250","volume":"2014","author":"SF Thomsen","year":"2014","unstructured":"Thomsen SF. Atopic dermatitis: natural history, diagnosis, and treatment. ISRN Allergy. 2014;2014: 354250. https:\/\/doi.org\/10.1155\/2014\/354250.","journal-title":"ISRN Allergy."},{"issue":"11","key":"1789_CR2","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1001\/jamadermatol.2022.3516","volume":"158","author":"TL Chen","year":"2022","unstructured":"Chen TL, Lee LL, Huang HK, Chen LY, Loh CH, Chi CC. Association of risk of incident venous thromboembolism with atopic dermatitis and treatment with janus kinase inhibitors: a systematic review and meta-analysis. JAMA Dermatol. 2022;158(11):1254\u201361. https:\/\/doi.org\/10.1001\/jamadermatol.2022.3516.","journal-title":"JAMA Dermatol"},{"issue":"2","key":"1789_CR3","doi-asserted-by":"publisher","first-page":"84","DOI":"10.2500\/aap.2019.40.4202","volume":"40","author":"J Kim","year":"2019","unstructured":"Kim J, Kim BE, Leung DYM. Pathophysiology of atopic dermatitis: clinical implications. Allergy Asthma Proc. 2019;40(2):84\u201392. https:\/\/doi.org\/10.2500\/aap.2019.40.4202.","journal-title":"Allergy Asthma Proc"},{"issue":"6","key":"1789_CR4","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s40257-020-00548-6","volume":"21","author":"S Ferreira","year":"2020","unstructured":"Ferreira S, Guttman-Yassky E, Torres T. Selective JAK1 inhibitors for the treatment of atopic dermatitis: focus on upadacitinib and abrocitinib. Am J Clin Dermatol. 2020;21(6):783\u201398. https:\/\/doi.org\/10.1007\/s40257-020-00548-6.","journal-title":"Am J Clin Dermatol"},{"issue":"3","key":"1789_CR5","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/j.jaci.2020.10.022","volume":"147","author":"W Damsky","year":"2021","unstructured":"Damsky W, Peterson D, Ramseier J, Al-Bawardy B, Chun H, Proctor D, et al. The emerging role of Janus kinase inhibitors in the treatment of autoimmune and inflammatory diseases. J Allergy Clin Immunol. 2021;147(3):814\u201326. https:\/\/doi.org\/10.1016\/j.jaci.2020.10.022.","journal-title":"J Allergy Clin Immunol"},{"key":"1789_CR6","doi-asserted-by":"publisher","first-page":"2020-8-5","DOI":"10.7573\/dic.2020-8-5","volume":"9","author":"N Nezamololama","year":"2020","unstructured":"Nezamololama N, Fieldhouse K, Metzger K, Gooderham M. Emerging systemic JAK inhibitors in the treatment of atopic dermatitis: a review of abrocitinib, baricitinib, and upadacitinib. Drugs Context. 2020;9:2020-8-5.\u00a0https:\/\/doi.org\/10.7573\/dic.2020-8-5.","journal-title":"Drugs Context."},{"issue":"4","key":"1789_CR7","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/j.jaci.2021.08.009","volume":"148","author":"R Chovatiya","year":"2021","unstructured":"Chovatiya R, Paller AS. JAK inhibitors in the treatment of atopic dermatitis. J Allergy Clin Immunol. 2021;148(4):927\u201340. https:\/\/doi.org\/10.1016\/j.jaci.2021.08.009.","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"1789_CR8","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/s40265-022-01694-3","volume":"82","author":"E Deeks","year":"2022","unstructured":"Deeks E, Duggan S. Correction to: Abrocitinib: first approval. Drugs. 2022;82(5):609. https:\/\/doi.org\/10.1007\/s40265-022-01694-3.","journal-title":"Drugs"},{"issue":"8","key":"1789_CR9","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1001\/jamadermatol.2020.1406","volume":"156","author":"JI Silverberg","year":"2020","unstructured":"Silverberg JI, Simpson EL, Thyssen JP, Gooderham M, Chan G, Feeney C, et al. Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2020;156(8):863\u201373. https:\/\/doi.org\/10.1001\/jamadermatol.2020.1406.","journal-title":"JAMA Dermatol"},{"issue":"3","key":"1789_CR10","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1111\/jdv.17813","volume":"36","author":"JP Thyssen","year":"2022","unstructured":"Thyssen JP, Yosipovitch G, Paul C, Kwatra SG, Chu CY, DiBonaventura M, et al. Patient-reported outcomes from the JADE COMPARE randomized phase 3 study of abrocitinib in adults with moderate-to-severe atopic dermatitis. J Eur Acad Dermatol Venereol. 2022;36(3):434\u201343. https:\/\/doi.org\/10.1111\/jdv.17813.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"9","key":"1789_CR11","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15636","volume":"35","author":"H Wan","year":"2022","unstructured":"Wan H, Jia H, Xia T, Zhang D. Comparative efficacy and safety of abrocitinib, baricitinib, and upadacitinib for moderate-to-severe atopic dermatitis: a network meta-analysis. Dermatol Ther. 2022;35(9): e15636. https:\/\/doi.org\/10.1111\/dth.15636.","journal-title":"Dermatol Ther"},{"issue":"5","key":"1789_CR12","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1001\/jamadermatol.2022.0455","volume":"158","author":"AM Drucker","year":"2022","unstructured":"Drucker AM, Morra DE, Prieto-Merino D, Ellis AG, Yiu ZZN, Rochwerg B, et al. Systemic immunomodulatory treatments for atopic dermatitis: update of a living systematic review and network meta-analysis. JAMA Dermatol. 2022;158(5):523\u201332. https:\/\/doi.org\/10.1001\/jamadermatol.2022.0455.","journal-title":"JAMA Dermatol"},{"issue":"1","key":"1789_CR13","doi-asserted-by":"publisher","first-page":"5","DOI":"10.2217\/imt-2021-0224","volume":"14","author":"T Bieber","year":"2022","unstructured":"Bieber T, Simpson EL, Silverberg JI, Thaci D, Paul C, Pink AE, et al. Comparing abrocitinib and dupilumab in the treatment of atopic dermatitis: a plain language summary. Immunotherapy. 2022;14(1):5\u201314. https:\/\/doi.org\/10.2217\/imt-2021-0224.","journal-title":"Immunotherapy"},{"issue":"6","key":"1789_CR14","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1111\/ijd.15853","volume":"61","author":"H Wood","year":"2022","unstructured":"Wood H, Chandler A, Nezamololama N, Papp K, Gooderham MJ. Safety of Janus kinase (JAK) inhibitors in the short-term treatment of atopic dermatitis. Int J Dermatol. 2022;61(6):746\u201354. https:\/\/doi.org\/10.1111\/ijd.15853.","journal-title":"Int J Dermatol"},{"key":"1789_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctim.2022.102872","volume":"71","author":"KH Han","year":"2022","unstructured":"Han KH, Cho KH, Han C, Cui S, Lin L, Baek HY, Kim J. The effectiveness and safety of acupuncture treatment on sciatica: a systematic review and meta-analysis. Complement Ther Med. 2022;71: 102872. https:\/\/doi.org\/10.1016\/j.ctim.2022.102872.","journal-title":"Complement Ther Med"},{"issue":"8","key":"1789_CR16","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1001\/jama.2011.1211","volume":"306","author":"C Ryan","year":"2011","unstructured":"Ryan C, Leonardi CL, Krueger JG, Kimball AB, Strober BE, Gordon KB, et al. Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials. JAMA. 2011;306(8):864\u201371. https:\/\/doi.org\/10.1001\/jama.2011.1211.","journal-title":"JAMA"},{"issue":"7414","key":"1789_CR17","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557\u201360. https:\/\/doi.org\/10.1136\/bmj.327.7414.557.","journal-title":"BMJ"},{"key":"1789_CR18","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovic J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366: l4898. https:\/\/doi.org\/10.1136\/bmj.l4898.","journal-title":"BMJ"},{"issue":"4","key":"1789_CR19","doi-asserted-by":"publisher","first-page":"279","DOI":"10.3390\/jpm11040279","volume":"11","author":"HR Tsai","year":"2021","unstructured":"Tsai HR, Lu JW, Chen LY, Chen TL. Application of Janus kinase inhibitors in atopic dermatitis: an updated systematic review and meta-analysis of clinical trials. J Pers Med. 2021;11(4):279. https:\/\/doi.org\/10.3390\/jpm11040279.","journal-title":"J Pers Med."},{"issue":"10290","key":"1789_CR20","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1016\/S0140-6736(21)00589-4","volume":"397","author":"K Reich","year":"2021","unstructured":"Reich K, Teixeira HD, de Bruin-Weller M, Bieber T, Soong W, Kabashima K, et al. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2021;397(10290):2169\u201381. https:\/\/doi.org\/10.1016\/S0140-6736(21)00589-4.","journal-title":"Lancet"},{"issue":"1","key":"1789_CR21","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.it.2014.10.006","volume":"36","author":"D Saleiro","year":"2015","unstructured":"Saleiro D, Platanias LC. Intersection of mTOR and STAT signaling in immunity. Trends Immunol. 2015;36(1):21\u20139. https:\/\/doi.org\/10.1016\/j.it.2014.10.006.","journal-title":"Trends Immunol"},{"issue":"3","key":"1789_CR22","doi-asserted-by":"publisher","first-page":"228","DOI":"10.2340\/00015555-1358","volume":"92","author":"BC Melnik","year":"2012","unstructured":"Melnik BC. Diet in acne: further evidence for the role of nutrient signalling in acne pathogenesis. Acta Derm Venereol. 2012;92(3):228\u201331. https:\/\/doi.org\/10.2340\/00015555-1358.","journal-title":"Acta Derm Venereol"},{"key":"1789_CR23","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.jdcr.2022.09.029","volume":"30","author":"SD Lee","year":"2022","unstructured":"Lee SD, Ahn HJ, Shin MK. A case series of acne following Janus kinase inhibitors in patients with atopic dermatitis. JAAD Case Rep. 2022;30:11\u20136. https:\/\/doi.org\/10.1016\/j.jdcr.2022.09.029.","journal-title":"JAAD Case Rep"},{"issue":"1","key":"1789_CR24","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14563","volume":"34","author":"SM Awad","year":"2021","unstructured":"Awad SM, Tawfik YM, El-Mokhtar MA, El-Gazzar AF, Abdel Motaleb AA. Activation of Janus kinase signaling pathway in acne lesions. Dermatol Ther. 2021;34(1): e14563. https:\/\/doi.org\/10.1111\/dth.14563.","journal-title":"Dermatol Ther"},{"issue":"6","key":"1789_CR25","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1111\/jdv.18027","volume":"36","author":"JP Thyssen","year":"2022","unstructured":"Thyssen JP, Nymand LK, Maul JT, Schmid-Grendelmeier P, Wu JJ, Thomsen SF, Egeberg A. Incidence, prevalence and risk of acne in adolescent and adult patients with atopic dermatitis: a matched cohort study. J Eur Acad Dermatol Venereol. 2022;36(6):890\u20136. https:\/\/doi.org\/10.1111\/jdv.18027.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1789_CR26","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v103.11657","volume":"103","author":"F Ballanger","year":"2023","unstructured":"Ballanger F, Auffret N, Leccia MT, Claudel JP, Dr\u00e9no B. Acneiform lesions but not acne after treatment with Janus kinase inhibitors: diagnosis and management of Janus kinase-acne. Acta Derm Venereol. 2023;103: adv11657. https:\/\/doi.org\/10.2340\/actadv.v103.11657.","journal-title":"Acta Derm Venereol"},{"issue":"4","key":"1789_CR27","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.jaad.2022.06.012","volume":"87","author":"P Mendes-Bastos","year":"2022","unstructured":"Mendes-Bastos P, Ladizinski B, Guttman-Yassky E, Jiang P, Liu J, Prajapati VH, et al. Characterization of acne associated with upadacitinib treatment in patients with moderate-to-severe atopic dermatitis: a post hoc integrated analysis of 3 phase 3 randomized, double-blind, placebo-controlled trials. J Am Acad Dermatol. 2022;87(4):784\u201391. https:\/\/doi.org\/10.1016\/j.jaad.2022.06.012.","journal-title":"J Am Acad Dermatol"},{"issue":"10348","key":"1789_CR28","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/s0140-6736(22)01199-0","volume":"400","author":"K Reich","year":"2022","unstructured":"Reich K, Thyssen JP, Blauvelt A, Eyerich K, Soong W, Rice ZP, et al. Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial. Lancet. 2022;400(10348):273\u201382. https:\/\/doi.org\/10.1016\/s0140-6736(22)01199-0.","journal-title":"Lancet"},{"issue":"1","key":"1789_CR29","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.jaad.2021.05.075","volume":"86","author":"A Blauvelt","year":"2022","unstructured":"Blauvelt A, Silverberg JI, Lynde CW, Bieber T, Eisman S, Zdybski J, et al. Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: results from the JAK1 Atopic dermatitis efficacy and safety (JADE) REGIMEN phase 3 trial. J Am Acad Dermatol. 2022;86(1):104\u201312. https:\/\/doi.org\/10.1016\/j.jaad.2021.05.075.","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"1789_CR30","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1001\/jamadermatol.2021.2830","volume":"157","author":"LF Eichenfield","year":"2021","unstructured":"Eichenfield LF, Flohr C, Sidbury R, Siegfried E, Szalai Z, Galus R, et al. Efficacy and safety of abrocitinib in combination with topical therapy in adolescents with moderate-to-severe atopic dermatitis: the JADE TEEN randomized clinical trial. JAMA Dermatol. 2021;157(10):1165\u201373. https:\/\/doi.org\/10.1001\/jamadermatol.2021.2830.","journal-title":"JAMA Dermatol"},{"issue":"10290","key":"1789_CR31","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1016\/S0140-6736(21)00588-2","volume":"397","author":"E Guttman-Yassky","year":"2021","unstructured":"Guttman-Yassky E, Teixeira HD, Simpson EL, Papp KA, Pangan AL, Blauvelt A, et al. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (measure Up 1 and measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials. Lancet. 2021;397(10290):2151\u201368. https:\/\/doi.org\/10.1016\/S0140-6736(21)00588-2.","journal-title":"Lancet"},{"issue":"9","key":"1789_CR32","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1001\/jamadermatol.2021.3023","volume":"157","author":"A Blauvelt","year":"2021","unstructured":"Blauvelt A, Teixeira HD, Simpson EL, Costanzo A, De Bruin-Weller M, Barbarot S, et al. Efficacy and safety of upadacitinib vs dupilumab in adults with moderate-to-severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2021;157(9):1047\u201355. https:\/\/doi.org\/10.1001\/jamadermatol.2021.3023.","journal-title":"JAMA Dermatol"},{"issue":"12","key":"1789_CR33","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1001\/jamadermatol.2020.3260","volume":"156","author":"K Reich","year":"2020","unstructured":"Reich K, Kabashima K, Peris K, Silverberg JI, Eichenfield LF, Bieber T, et al. Efficacy and safety of baricitinib combined with topical corticosteroids for treatment of moderate to severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2020;156(12):1333\u201343. https:\/\/doi.org\/10.1001\/jamadermatol.2020.3260.","journal-title":"JAMA Dermatol"}],"container-title":["Inflammation Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00011-023-01789-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00011-023-01789-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00011-023-01789-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T05:04:03Z","timestamp":1695877443000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00011-023-01789-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":33,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["1789"],"URL":"https:\/\/doi.org\/10.1007\/s00011-023-01789-x","relation":{},"ISSN":["1023-3830","1420-908X"],"issn-type":[{"value":"1023-3830","type":"print"},{"value":"1420-908X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"27 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All authors have read and approved of the final version of the manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate\/publish"}}]}}